Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Hormonal / allergy — Net revenue

Other product segments

Subtotal dosage forms
$417.92M+1.1%
Oral solid
$171.1M-4.4%
Subtotal therapeutic classes
$133.27M+23.1%
Distribution
$89.15M-15.0%
Central nervous system
$83.38M+23.3%
Transdermal
$73.96M+71.8%
Government label
$59.95M+19.6%
Injectable
$49.94M+43.5%
Other dosage forms
$46.61M-17.4%
Auto-Injector
$41.91M-13.0%
Biosimilar
$22.3M-21.9%
Other therapeutic classes
$13.95M+115%
Oral liquid
$12.09M-48.6%
Institutional
$9.82M-10.8%
International
$5.32M+331%

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×—
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported hormonal / allergy — net revenue of $35.93M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue increased by 5.1% year-over-year, from $34.2M to $35.93M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue?
Over 2 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue has grown at a -44.1% compound annual growth rate (CAGR), from $495.47M to $154.93M.
What does hormonal / allergy — net revenue mean?
This metric represents the total gross sales generated by the hormonal and allergy product portfolio after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for this specific therapeutic category within the company's broader pharmaceutical offerings. Tracking this revenue stream helps investors assess the segment's contribution to overall top-line growth and its competitive positioning in the specialized pharmaceutical market.